Clinical Trial

A Study of LY4175408 in Participants With Advanced Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years.
Protocol Amendment History 1 change
minor Trial arms changed: 3 -> 5 2026-06-03
Trial Details
NCT Number NCT07046923
Lead Sponsor Eli Lilly and Company
Conditions Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis, Triple Negative Breast Cancer
Enrollment 240 participants
Start Date 2025-07-28
Primary Completion 2030-07 (estimated)
Study Completion 2030-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-23